Neurones
France · FR0004050250 · reports in EUR · Europe
The answers
From the annual report for the year to Dec 31, 2025. Each line says what it is based on.
- Is it growing?Fair
- Revenue +5.8% in the year to Dec 31, 2025, on the year before.
- Is it a good business?Fair
- It earned 13% on its shareholders' equity in the year to Dec 31, 2025.
- Is it safe?Good
- Equity is 62% of its assets, and operations brought in cash in the year.
- Is the price fair?n/a
- Not answered: no exchange publishes this company's price for free reuse, so there is no P/E here.
The year
Year to Dec 31, 2025, consolidated, in EUR.
€857M
revenue
8.8%
operating margin
€52M
net profit
Year by year
As filed; an earlier year can differ from its own report when the company restated it.
| Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | |
|---|---|---|---|---|
| Revenue | €665M | €741M | €810M | €857M |
| Operating profit | €73M | €76M | €78M | €76M |
| Net profit to shareholders | €44M | €49M | €53M | €52M |
| Earnings per share | €1.83 | €2.04 | €2.17 | €2.14 |
| Cash from operations | €55M | €72M | €84M | €71M |
| Cash | €272M | €298M | €326M | €341M |
| Total assets | €616M | €674M | €726M | €749M |
| Equity | €376M | €408M | €436M | €465M |
What they do
In the company's own words, from the annual report.
Le groupe exerce des activités de Conseil et de Services Numériques.
Source: the company’s annual financial report in ESEF, via filings.xbrl.org (XBRL International). Listed shares from ESMA’s FIRDS register; ESMA does not endorse this site. Ryufin computed the answers and ratios from the filed figures.